In vitro susceptibility of selected veterinary bacterial pathogens to ciprofloxacin, enrofloxacin and norfloxacin.
The minimum inhibitory concentrations (MIC) of ciprofloxacin, enrofloxacin, and norfloxacin were tested for approximately ten clinical isolates of each of Actinobacillus pleuropneumoniae, Actinobacillus suis, Actinomyces pyogenes, Corynebacterium pseudotuberculosis, Erysipelothrix rhusiopathiae, Haemophilus parasuis, Haemophilus somnus, Pasteurella haemolytica, Pasteurella multocida, Rhodococcus equi, Streptococcus equi, Streptococcus suis and Streptococcus zooepidemicus. Ciprofloxacin and enrofloxacin had similar activity and were more active than norfloxacin. All isolates had an MIC of 1.0 microgram/mL or less for ciprofloxacin and enrofloxacin, and these drugs had particularly marked activity against the gram-negative bacteria tested.
Prescott
J F
JF
Department of Veterinary Microbiology and Immunology, Ontario Veterinary College, University of Guelph.
Yielding
K M
KM
D000188:Actinobacillus / Q000187:drug effects*; D000190:Actinomyces / Q000187:drug effects*; D000890:Anti-Infective Agents / Q000494:pharmacology*; D002939:Ciprofloxacin / Q000494:pharmacology*; D003352:Corynebacterium / Q000187:drug effects*; D000077422:Enrofloxacin; D004888:Erysipelothrix / Q000187:drug effects*; D024841:Fluoroquinolones; D006190:Haemophilus / Q000187:drug effects*; D066298:In Vitro Techniques; D008826:Microbial Sensitivity Tests; D009643:Norfloxacin / Q000494:pharmacology*; D010325:Pasteurella / Q000187:drug effects*; D015363:Quinolones; D012240:Rhodococcus / Q000187:drug effects*; D013291:Streptococcus / Q000187:drug effects*
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; D000077422:Enrofloxacin; D002939:Ciprofloxacin; D009643:Norfloxacin